47 results on '"Cai, Weibo"'
Search Results
2. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617
- Author
-
Lu, Qiaomiao, Long, Yu, Fan, Kevin, Shen, Zhiwen, Gai, Yongkang, Liu, Qingyao, Jiang, Dawei, Cai, Weibo, Wan, Chidan, and Lan, Xiaoli
- Published
- 2022
- Full Text
- View/download PDF
3. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond
- Author
-
Li, Mengting, Younis, Muhsin H., Zhang, Yongxue, Cai, Weibo, and Lan, Xiaoli
- Published
- 2022
- Full Text
- View/download PDF
4. ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer
- Author
-
Chen, Weiyu, Li, Miao, Younis, Muhsin H., Barnhart, Todd E., Jiang, Dawei, Sun, Tuanwei, Lang, Joshua M., Engle, Jonathan W., Zhou, Min, and Cai, Weibo
- Published
- 2022
- Full Text
- View/download PDF
5. ImmunoPET: The Future of Response Evaluation for Cancer Immunotherapy
- Author
-
Ehlerding, Emily B., Cai, Weibo, Lopci, Egesta, editor, and Fanti, Stefano, editor
- Published
- 2020
- Full Text
- View/download PDF
6. ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab
- Author
-
Kang, Lei, Jiang, Dawei, England, Christopher G., Barnhart, Todd E., Yu, Bo, Rosenkrans, Zachary T., Wang, Rongfu, Engle, Jonathan W., Xu, Xiaojie, Huang, Peng, and Cai, Weibo
- Published
- 2018
- Full Text
- View/download PDF
7. 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer
- Author
-
England, Christopher G., Jiang, Dawei, Ehlerding, Emily B., Rekoske, Brian T., Ellison, Paul A., Hernandez, Reinier, Barnhart, Todd E., McNeel, Douglas G., Huang, Peng, and Cai, Weibo
- Published
- 2018
- Full Text
- View/download PDF
8. PET and SPECT imaging of melanoma: the state of the art
- Author
-
Wei, Weijun, Ehlerding, Emily B., Lan, Xiaoli, Luo, Quanyong, and Cai, Weibo
- Published
- 2018
- Full Text
- View/download PDF
9. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer
- Author
-
Jiang, Dawei, Im, Hyung-Jun, Sun, Haiyan, Valdovinos, Hector F., England, Christopher G., Ehlerding, Emily B., Nickles, Robert J., Lee, Dong Soo, Cho, Steve Y., Huang, Peng, and Cai, Weibo
- Published
- 2017
- Full Text
- View/download PDF
10. Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry
- Author
-
Luo, Haiming, Hernandez, Reinier, Hong, Hao, Graves, Stephen A., Yang, Yunan, England, Christopher G., Theuer, Charles P., Nickles, Robert J., and Cai, Weibo
- Published
- 2015
11. In Vivo Tumor-Targeted Dual-Modality PET/Optical Imaging with a Yolk/Shell-Structured Silica Nanosystem
- Author
-
Shi, Sixiang, Chen, Feng, Goel, Shreya, Graves, Stephen A., Luo, Haiming, Theuer, Charles P., Engle, Jonathan W., and Cai, Weibo
- Published
- 2018
- Full Text
- View/download PDF
12. One-step synthesis of an 18F-labeled boron-derived methionine analog: a substitute for 11C-methionine?
- Author
-
Liu, Zhen, Ehlerding, Emily B., Cai, Weibo, and Lan, Xiaoli
- Published
- 2018
- Full Text
- View/download PDF
13. ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer
- Author
-
Sun, Haiyan, England, Christopher G., Hernandez, Reinier, Graves, Stephen A., Majewski, Rebecca L., Kamkaew, Anyanee, Jiang, Dawei, Barnhart, Todd E., Yang, Yunan, and Cai, Weibo
- Published
- 2016
- Full Text
- View/download PDF
14. Evaluation of two novel 64Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αvβ3
- Author
-
Hernandez, Reinier, Czerwinski, Andrzej, Chakravarty, Rubel, Graves, Stephen A., Yang, Yunan, England, Christopher G., Nickles, Robert J., Valenzuela, Francisco, and Cai, Weibo
- Published
- 2015
- Full Text
- View/download PDF
15. ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment
- Author
-
Shi, Sixiang, Hong, Hao, Orbay, Hakan, Graves, Stephen A., Yang, Yunan, Ohman, Jakob D., Liu, Bai, Nickles, Robert J., Wong, Hing C., and Cai, Weibo
- Published
- 2015
- Full Text
- View/download PDF
16. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617.
- Author
-
Lu, Qiaomiao, Long, Yu, Fan, Kevin, Shen, Zhiwen, Gai, Yongkang, Liu, Qingyao, Jiang, Dawei, Cai, Weibo, Wan, Chidan, and Lan, Xiaoli
- Subjects
HEPATOCELLULAR carcinoma ,POSITRON emission tomography ,PROSTATE-specific membrane antigen ,PHARMACOKINETICS ,ENDOTHELIAL cells - Abstract
Objective: Hepatocellular carcinoma (HCC) is a malignant tumor associated with high morbidity and mortality rates. In many non-prostate solid tumors such as HCC, prostate-specific membrane antigens (PSMA) are overexpressed in tumor-associated endothelial cells. Therefore, the aim of this study was to evaluate the performance of [
68 Ga]Ga-PSMA-617 PET imaging on HCC with different animal models, including cell line-derived xenografts (CDX) and patient-derived xenografts (PDX), and to explore its mechanisms of function. Methods: [68 Ga]Ga-PSMA-617 was prepared. The expression level of PSMA in two human hepatocellular cancer cells (HepG2 and HuH-7) was evaluated, and the cellular uptakes of [68 Ga]Ga-PSMA-617 were assayed. HepG2 and HuH-7 subcutaneous xenograft models, HepG2 orthotopic xenograft models, and four different groups of PDX models were prepared. Preclinical pharmacokinetics and performance of [68 Ga]Ga-PSMA-617 were evaluated in different types of HCC xenografts models using small animal PET and biodistribution studies. Results: Low PSMA expression level of HepG2 and HuH-7 cells was observed, and the cellular uptake and blocking study confirmed the non-specificity of the PSMA-targeted probe binding to HepG2 and HuH-7 cells. In the subcutaneous xenograft models, the tumor uptakes at 0.5 h were 0.76 ± 0.12%ID/g (HepG2 tumors) and 0.78 ± 0.08%ID/g (HuH-7 tumors), respectively, which were significantly higher than those of the blocking groups (0.23 ± 0.04%ID/g and 0.20 ± 0.04%ID/g, respectively). In the orthotopic xenograft models, PET images clearly displayed the tumor locations based on the preferential accumulation of [68 Ga]Ga-PSMA-617 in tumor tissue versus normal liver tissue, suggesting the possibility of using [68 Ga]Ga-PSMA-617 PET imaging to detect primary HCC lesions in deep tissue. In the four different groups of HCC PDX models, PET imaging with [68 Ga]Ga-PSMA-617 provided clear tumor uptakes with prominent tumor-to-background contrast, further demonstrating its potential for the clinical imaging of PSMA-positive HCC lesions. The staining of tumor tissue sections with CD31- and PSMA-specific antibodies visualized the tumor-associated blood vessels and PSMA expression on endothelial cells in subcutaneous, orthotopic tissues, and PDX tissues, confirming the imaging with [68 Ga]Ga-PSMA-617 might be mediated by targeting tumor associated endothelium. Conclusion: In this study, in vivo PET on different types of HCC xenograft models illustrated high uptake within tumors, which confirmed that [68 Ga]Ga-PSMA-617 PET may be a promising imaging modality for HCC by targeting tumor associated endothelium. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
17. Pharmacokinetic Issues of Imaging with Nanoparticles: Focusing on Carbon Nanotubes and Quantum Dots
- Author
-
Hong, Hao, Chen, Feng, and Cai, Weibo
- Published
- 2013
- Full Text
- View/download PDF
18. Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence
- Author
-
Zhang, Yin, Hong, Hao, Nayak, Tapas R., Valdovinos, Hector F., Myklejord, Duane V., Theuer, Charles P., Barnhart, Todd E., and Cai, Weibo
- Published
- 2013
- Full Text
- View/download PDF
19. PET imaging of CD105/endoglin expression with a 61/64Cu-labeled Fab antibody fragment
- Author
-
Zhang, Yin, Hong, Hao, Orbay, Hakan, Valdovinos, Hector F., Nayak, Tapas R., Theuer, Charles P., Barnhart, Todd E., and Cai, Weibo
- Published
- 2013
- Full Text
- View/download PDF
20. PET/SPECT imaging of hindlimb ischemia: focusing on angiogenesis and blood flow
- Author
-
Orbay, Hakan, Hong, Hao, Zhang, Yin, and Cai, Weibo
- Published
- 2013
- Full Text
- View/download PDF
21. Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105
- Author
-
Hong, Hao, Severin, Gregory W., Yang, Yunan, Engle, Jonathan W., Zhang, Yin, Barnhart, Todd E., Liu, Glenn, Leigh, Bryan R., Nickles, Robert J., and Cai, Weibo
- Published
- 2012
- Full Text
- View/download PDF
22. Positron emission tomography imaging of CD105 expression during tumor angiogenesis
- Author
-
Hong, Hao, Yang, Yunan, Zhang, Yin, Engle, Jonathan W., Barnhart, Todd E., Nickles, Robert J., Leigh, Bryan R., and Cai, Weibo
- Published
- 2011
- Full Text
- View/download PDF
23. Quantitative PET Imaging of VEGF Receptor Expression
- Author
-
Chen, Kai, Cai, Weibo, Li, Zi-Bo, Wang, Hui, and Chen, Xiaoyuan
- Published
- 2009
- Full Text
- View/download PDF
24. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots
- Author
-
Chen, Kai, Li, Zi-Bo, Wang, Hui, Cai, Weibo, and Chen, Xiaoyuan
- Published
- 2008
- Full Text
- View/download PDF
25. Non-Invasive PET Imaging of EGFR Degradation Induced by a Heat Shock Protein 90 Inhibitor
- Author
-
Niu, Gang, Cai, Weibo, Chen, Kai, and Chen, Xiaoyuan
- Published
- 2008
- Full Text
- View/download PDF
26. CD38‐Targeted Theranostics of Lymphoma with 89Zr/177Lu‐Labeled Daratumumab.
- Author
-
Kang, Lei, Li, Cuicui, Rosenkrans, Zachary T., Huo, Nan, Chen, Zhao, Ehlerding, Emily B., Huo, Yan, Ferreira, Carolina A., Barnhart, Todd E., Engle, Jonathan W., Wang, Rongfu, Jiang, Dawei, Xu, Xiaojie, and Cai, Weibo
- Subjects
DARATUMUMAB ,B cell lymphoma ,BURKITT'S lymphoma ,POSITRON emission tomography ,LYMPHOMAS - Abstract
Lymphoma is a heterogeneous disease with varying clinical manifestations and outcomes. Many subtypes of lymphoma, such as Burkitt′s lymphoma and diffuse large B cell lymphoma, are highly aggressive with dismal prognosis even after conventional chemotherapy and radiotherapy. As such, exploring specific biomarkers for lymphoma is of high clinical significance. Herein, a potential marker, CD38, is investigated for differentiating lymphoma. A CD38‐targeting monoclonal antibody (mAb, daratumumab) is then radiolabeled with Zr‐89 and Lu‐177 for theranostic applications. As the diagnostic component, the Zr‐89‐labeled mAb is highly specific in delineating CD38‐positive lymphoma via positron emission tomography (PET) imaging, while the Lu‐177‐labeled mAb serves well as the therapeutic component to suppress tumor growth after a one‐time administration. These results strongly suggest that CD38 is a lymphoma‐specific marker and prove that 89Zr/177Lu‐labeled daratumumab facilitates immunoPET imaging and radioimmunotherapy of lymphoma in preclinical models. Further clinical evaluation and translation of this CD38‐targeted theranostics may be of significant help in lymphoma patient stratification and management. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab.
- Author
-
Kang, Lei, Jiang, Dawei, England, Christopher G., Barnhart, Todd E., Yu, Bo, Rosenkrans, Zachary T., Wang, Rongfu, Engle, Jonathan W., Xu, Xiaojie, Huang, Peng, and Cai, Weibo
- Subjects
POSITRON emission tomography ,BCL-2 proteins ,CD38 antigen ,HEMATOLOGICAL oncology ,CANCER - Abstract
Purpose: CD38 is considered a potential biomarker for multiple myeloma (MM) and has shown a strong link with chronic lymphocytic leukemia due to high and uniform expression on plasma cells. In vivo evaluation of CD38 expression may provide useful information about lesion detection and prognosis of treatment in MM. In this study, immunoPET imaging with
89 Zr-labeled daratumumab was used for differentiation of CD38 expression in murine lymphoma models to provide a potential non-invasive method for monitoring CD38 in the clinic.Methods: Daratumumab was radiolabeled with89 Zr (t1/2 = 78.4 h) via conjugation with desferrioxamine (Df). After Western blot (WB) was used to screen CD38 expression in five lymphoma cell lines, flow cytometry and cellular binding assays were performed to test the binding ability of labeled or conjugated daratumumab with CD38 in vitro. PET imaging and biodistribution studies were performed to evaluate CD38 expression after injection of89 Zr-Df-daratumumab.89 Zr-Df-IgG was also evaluated as a non-specific control group in the Ramos model. Finally, CD38 expression in tumor tissues was verified by histological analysis.Results: Using WB screening, the Ramos cell line was found to express the highest level of CD38 while the HBL-1 cell line had the lowest expression. Df-conjugated and89 Zr-labeled daratumumab displayed similar high binding affinities with Ramos cells. PET imaging of89 Zr-Df-daratumumab showed a high tumor uptake of up to 26.6 ± 8.0 %ID/g for Ramos at 120 h post-injection, and only up to 6.6 ± 2.9 %ID/g for HBL-1 (n = 4). Additionally,89 Zr-Df-IgG demonstrated a low tumor uptake in the Ramos model (only 4.3 ± 0.8 %ID/g at 120 h post-injection). Ex vivo biodistribution studies showed similar trends with imaging results. Immunofluorescence staining of tumor tissues verified higher CD38 expression of Ramos than that of HBL-1.Conclusions: The role of89 Zr-Df-daratumumab was investigated for evaluating CD38 expression in lymphoma models non-invasively and was found to be to a promising imaging agent of CD38-positive hematological diseases such as MM in future clinical applications. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
28. Uptake and retention of manganese contrast agents for PET and MRI in the rodent brain.
- Author
-
Brunnquell, Christina L., Hernandez, Reinier, Graves, Stephen A., Smit-Oistad, Ivy, Nickles, Robert J., Cai, Weibo, Meyerand, M. Elizabeth, and Suzuki, Masatoshi
- Abstract
Manganese-enhanced magnetic resonance imaging (MRI) is an established neuroimaging method for signal enhancement, tract tracing, and functional studies in rodents. Along with the increasing availability of combined positron emission tomography (PET) and MRI scanners, the recent development of the positron-emitting isotope
52 Mn has prompted interest in the use of Mn2+ as a dual-modality contrast agent. In this work, we characterized and compared the uptake of systemically delivered Mn2+ and radioactive52 Mn2+ in the rat brain for MRI and PET, respectively. Additionally, we examined the biodistribution of two formulations of52 Mn2+ in the rat. In MRI, maximum uptake was observed one day following delivery of the highest MnCl2 dose tested (60 mg/kg), with some brain regions showing delayed maximum enhancement 2-4 days following delivery. In PET, we observed low brain uptake after systemic delivery, with a maximum of approximately 0.2% ID/g. We also studied the effect of final formulation vehicle (saline compared with MnCl2 ) on52 Mn2+ organ biodistribution and brain uptake. We observed that the addition of bulk Mn2+ carrier to52 Mn2+ in solution resulted in significantly reduced52 Mn2+ uptake in the majority of organs, including the brain. These results lay the groundwork for further development of52 Mn PET or dual Mn-enhanced PET-MR neuroimaging in rodents, and indicate several interesting potential applications of52 Mn PET in other organs and systems. Copyright © 2016 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
29. Evaluation of two novel Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αβ.
- Author
-
Hernandez, Reinier, Czerwinski, Andrzej, Chakravarty, Rubel, Graves, Stephen A., Yang, Yunan, England, Christopher, Nickles, Robert, Valenzuela, Francisco, and Cai, Weibo
- Subjects
TUMORS ,RADIOACTIVE tracers ,TRACERS (Biology) ,CARRIER proteins ,PHARMACOKINETICS - Abstract
Purpose: Our goal was to demonstrate that suitably derivatized monomeric RGD peptide-based PET tracers, targeting integrin αβ, may offer advantages in image contrast, time for imaging, and low uptake in nontarget tissues. Methods: Two cyclic RGDfK derivatives, (PEG)-c(RGDfK) and PEG-SAA-c(RGDfK), were constructed and conjugated to NOTA for Cu labeling. Their integrin αβ-binding properties were determined via a competitive cell binding assay. Mice bearing U87MG tumors were intravenously injected with each of the Cu-labeled peptides, and PET scans were acquired during the first 30 min, and 2 and 4 h after injection. Blocking and ex vivo biodistribution studies were carried out to validate the PET data and confirm the specificity of the tracers. Results: The IC values of NOTA-(PEG)-c(RGDfK) and NOTA-PEG-SAA-c(RGDfK) were 444 ± 41 nM and 288 ± 66 nM, respectively. Dynamic PET data of Cu-NOTA-(PEG)-c(RGDfK) and Cu-NOTA-PEG-SAA-c(RGDfK) showed similar circulation t and peak tumor uptake of about 4 %ID/g for both tracers. Due to its marked hydrophilicity, Cu-NOTA-PEG-SAA-c(RGDfK) provided faster clearance from tumor and normal tissues yet maintained excellent tumor-to-background ratios. Static PET scans at later time-points corroborated the enhanced excretion of the tracer, especially from abdominal organs. Ex vivo biodistribution and receptor blocking studies confirmed the accuracy of the PET data and the integrin αβ-specificity of the peptides. Conclusion: Our two novel RGD-based radiotracers with optimized pharmacokinetic properties allowed fast, high-contrast PET imaging of tumor-associated integrin αβ. These tracers may facilitate the imaging of abdominal malignancies, normally precluded by high background uptake. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
30. One-step synthesis of an 18F-labeled boron-derived methionine analog: a substitute for 11C-methionine?
- Author
-
Liu, Zhen, Ehlerding, Emily B., Cai, Weibo, and Lan, Xiaoli
- Subjects
POSITRON emission tomography ,GLIOMAS ,BRAIN tumors ,METHIONINE ,RADIOLABELING ,PATIENTS ,DIAGNOSIS ,THERAPEUTICS - Abstract
Amino acid-based tracers have been extensively investigated for positron emission tomography (PET) imaging of brain tumors, and
11 C-methionine (11 C-MET) is one of the most extensively investigated. However, widespread clinical use of11 C-MET is challenging due to the short half-life of11 C and low radiolabeling yield. In this issue of theEuropean Journal of Nuclear Medicine and Molecular Imaging , Yang and colleagues report an18 F-labeled boron-derived methionine analog,18 F-B-MET, as a potential substitute for11 C-MET in PET imaging of glioma. The push-button synthesis, highly efficient radiolabeling, and good imaging performance in glioma models make this tracer a promising candidate for future clinical translation. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
31. Radionuclide-Based Imaging of Breast Cancer: State of the Art.
- Author
-
Li, Huiling, Liu, Zhen, Yuan, Lujie, Fan, Kevin, Zhang, Yongxue, Cai, Weibo, and Lan, Xiaoli
- Subjects
BREAST cancer prognosis ,BREAST tumor diagnosis ,MOLECULAR diagnosis ,EARLY detection of cancer ,MEDICAL technology ,RADIOISOTOPES ,RADIONUCLIDE imaging ,DIAGNOSTIC imaging ,SINGLE-photon emission computed tomography ,TUMOR markers ,BREAST tumors - Abstract
Simple Summary: Breast cancer is one of the most commonly diagnosed malignant tumors, possessing high incidence and mortality rates that threaten women's health. Thus, early and effective breast cancer diagnosis is crucial for enhancing the survival rate. Radionuclide molecular imaging displays its advantages for detecting breast cancer from a functional perspective. Noninvasive visualization of biological processes with radionuclide-labeled small metabolic compounds helps elucidate the metabolic state of breast cancer, while radionuclide-labeled ligands/antibodies for receptor-targeted radionuclide molecular imaging is sensitive and specific for visualization of the overexpressed molecular markers in breast cancer. This review focuses on the most recent developments of novel radiotracers as promising tools for early breast cancer diagnosis. Breast cancer is a malignant tumor that can affect women worldwide and endanger their health and wellbeing. Early detection of breast cancer can significantly improve the prognosis and survival rate of patients, but with traditional anatomical imagine methods, it is difficult to detect lesions before morphological changes occur. Radionuclide-based molecular imaging based on positron emission tomography (PET) and single-photon emission computed tomography (SPECT) displays its advantages for detecting breast cancer from a functional perspective. Radionuclide labeling of small metabolic compounds can be used for imaging biological processes, while radionuclide labeling of ligands/antibodies can be used for imaging receptors. Noninvasive visualization of biological processes helps elucidate the metabolic state of breast cancer, while receptor-targeted radionuclide molecular imaging is sensitive and specific for visualization of the overexpressed molecular markers in breast cancer, contributing to early diagnosis and better management of cancer patients. The rapid development of radionuclide probes aids the diagnosis of breast cancer in various aspects. These probes target metabolism, amino acid transporters, cell proliferation, hypoxia, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), gastrin-releasing peptide receptor (GRPR) and so on. This article provides an overview of the development of radionuclide molecular imaging techniques present in preclinical or clinical studies, which are used as tools for early breast cancer diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. PET imaging of CD105/endoglin expression with a Cu-labeled Fab antibody fragment.
- Author
-
Zhang, Yin, Hong, Hao, Orbay, Hakan, Valdovinos, Hector, Nayak, Tapas, Theuer, Charles, Barnhart, Todd, and Cai, Weibo
- Subjects
ENDOGLIN ,MONOCLONAL antibodies ,POSITRON emission tomography ,BREAST cancer ,IMMUNOFLUORESCENCE - Abstract
Purpose: The goal of this study was to generate and characterize the Fab fragment of TRC105, a monoclonal antibody that binds with high affinity to human and murine CD105 (i.e., endoglin), and investigate its potential for PET imaging of tumor angiogenesis in a small-animal model after Cu labeling. Methods: TRC105-Fab was generated by enzymatic papain digestion. The integrity and CD105 binding affinity of TRC105-Fab was evaluated before NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) conjugation and Cu labeling. Serial PET imaging and biodistribution studies were carried out in the syngeneic 4T1 murine breast cancer model to quantify tumor targeting efficiency and normal organ distribution of Cu-NOTA-TRC105-Fab. Blocking studies with unlabeled TRC105 were performed to confirm CD105 specificity of the tracer in vivo. Immunofluorescence staining was also conducted to correlate tracer uptake in the tumor and normal tissues with CD105 expression. Results: TRC105-Fab was produced with high purity through papain digestion of TRC105, as confirmed by SDS-PAGE, HPLC analysis, and mass spectrometry. Cu labeling of NOTA-TRC105-Fab was achieved with about 50 % yield (specific activity about 44 GBq/μmol). PET imaging revealed rapid uptake of Cu-NOTA-TRC105-Fab in the 4T1 tumor (3.6 ± 0.4, 4.2 ± 0.5, 4.9 ± 0.3, 4.4 ± 0.7, and 4.6 ± 0.8 %ID/g at 0.5, 2, 5, 16, and 24 h after injection, respectively; n = 4). Since tumor uptake peaked soon after tracer injection, Cu-labeled TRC105-Fab was also able to provide tumor contrast at 3 and 8 h after injection. CD105 specificity of the tracer was confirmed with blocking studies and histological examination. Conclusion: We report PET imaging of CD105 expression using Cu-NOTA-TRC105-Fab, which exhibited prominent and target-specific uptake in the 4T1 tumor. The use of a Fab fragment led to much faster tumor uptake (which peaked at a few hours after tracer injection) compared to radiolabeled intact antibody, which may be translated into same-day immunoPET imaging for clinical investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
33. Positron emission tomography imaging of CD105 expression with Zr-Df-TRC105.
- Author
-
Hong, Hao, Severin, Gregory, Yang, Yunan, Engle, Jonathan, Zhang, Yin, Barnhart, Todd, Liu, Glenn, Leigh, Bryan, Nickles, Robert, and Cai, Weibo
- Subjects
POSITRON emission tomography ,IMMUNOHISTOCHEMISTRY ,DRUG metabolism ,MONOCLONAL antibodies ,DEFEROXAMINE ,TUMORS - Abstract
Purpose: High tumor microvessel density correlates with a poor prognosis in multiple solid tumor types. The clinical gold standard for assessing microvessel density is CD105 immunohistochemistry on paraffin-embedded tumor specimens. The goal of this study was to develop an Zr-based PET tracer for noninvasive imaging of CD105 expression. Methods: TRC105, a chimeric anti-CD105 monoclonal antibody, was conjugated to p-isothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS) and labeled with Zr. FACS analysis and microscopy studies were performed to compare the CD105 binding affinity of TRC105 and Df-TRC105. PET imaging, biodistribution, blocking, and ex-vivo histology studies were performed on 4T1 murine breast tumor-bearing mice to evaluate the pharmacokinetics and tumor-targeting of Zr-Df-TRC105. Another chimeric antibody, cetuximab, was used as an isotype-matched control. Results: FACS analysis of HUVECs revealed no difference in CD105 binding affinity between TRC105 and Df-TRC105, which was further validated by fluorescence microscopy. Zr labeling was achieved with high yield and specific activity. Serial PET imaging revealed that the 4T1 tumor uptake of Zr-Df-TRC105 was 6.1 ± 1.2, 14.3 ± 1.2, 12.4 ± 1.5, 7.1 ± 0.9, and 5.2 ± 0.3 %ID/g at 5, 24, 48, 72, and 96 h after injection, respectively ( n = 4), higher than all organs starting from 24 h after injection, which provided excellent tumor contrast. Biodistribution data as measured by gamma counting were consistent with the PET findings. Blocking experiments, control studies with Zr-Df-cetuximab, and ex-vivo histology all confirmed the in vivo target specificity of Zr-Df-TRC105. Conclusion: We report here the first successful PET imaging of CD105 expression with Zr as the radiolabel. Rapid, persistent, CD105-specific uptake of Zr-Df-TRC105 in the 4T1 tumor was observed. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
34. Molecular imaging and therapy of cancer with radiolabeled nanoparticles.
- Author
-
Hong, Hao, Zhang, Yin, Sun, Jiangtao, and Cai, Weibo
- Subjects
MOLECULAR diagnosis ,CANCER radiotherapy ,RADIOLABELING ,NANOPARTICLES ,POSITRON emission tomography ,CANCER tomography - Abstract
Summary: This review summarizes the current state-of-the-art of radiolabeled nanoparticles for molecular imaging and internal radiotherapy applications targeting cancer. With the capacity to provide enormous flexibility, radiolabeled nanoparticles have the potential to profoundly impact disease diagnosis and patient management in the near future. Currently, the major challenges facing the research on radiolabeled nanoparticles are desirable (tumor) targeting efficacy, robust chemistry for both radionuclide encapsulation/incorporation and targeting ligand conjugation, favorable safety profile, as well as certain commercial and regulatory hurdles. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
35. Molecular imaging with single-walled carbon nanotubes.
- Author
-
Hong, Hao, Gao, Ting, and Cai, Weibo
- Subjects
CARBON nanotubes ,TOMOGRAPHY ,NANOPARTICLES ,RAMAN spectroscopy - Abstract
Summary: Nanoparticle-based molecular imaging has emerged as an interdisciplinary field which involves physics, chemistry, engineering, biology, and medicine. Single-walled carbon nanotubes (SWCNTs) have unique properties which make them suitable for applications in a variety of imaging modalities, such as magnetic resonance, near-infrared fluorescence, Raman spectroscopy, photoacoustic tomography, and radionuclide-based imaging. In this review, we will summarize the current state-of-the-art of SWCNTs in molecular imaging applications. Multifunctionality is the key advantage of nanoparticles over traditional approaches. Targeting ligands, imaging labels, therapeutic drugs, and many other agents can all be integrated into the nanoparticle to allow for targeted molecular imaging and molecular therapy by encompassing many biological and biophysical barriers. A multifunctional, SWCNT-based nanoplatform holds great potential for clinical applications in the future. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
36. Head-to-Head Comparison of Neck 18 F-FDG PET/MR and PET/CT in the Diagnosis of Differentiated Thyroid Carcinoma Patients after Comprehensive Treatment.
- Author
-
Song, Yangmeihui, Liu, Fang, Ruan, Weiwei, Hu, Fan, Younis, Muhsin H., Gao, Zairong, Ming, Jie, Huang, Tao, Cai, Weibo, and Lan, Xiaoli
- Subjects
PREDICTIVE tests ,ACQUISITION of data methodology ,THYROID gland tumors ,MAGNETIC resonance imaging ,RETROSPECTIVE studies ,LYMPH nodes ,METASTASIS ,CANCER relapse ,RADIOPHARMACEUTICALS ,MEDICAL records ,DESCRIPTIVE statistics ,DEOXY sugars - Abstract
Simple Summary: The most advanced positron emission tomography–magnetic resonance (PET/MR) combines the high soft tissue contrast of MRI with the high functional/metabolic sensitivity of PET and has the potential to achieve the highest level of diagnostic performance for refractory malignancies in differentiated thyroid cancer (DTC) patients. The utility of PET/MR in the postoperative follow-up of DTC patients has been relatively ambiguous. This retrospective study compared
18 F-fluorodeoxyglucose neck PET/MR with PET/CT head-to-head, in order to evaluate the diagnostic efficacy of PET/MR in assessment malignancy in DTC patients after comprehensive treatment. We determined that PET/MR presented better detection rates, image conspicuity, and sensitivity than PET/CT in recurrent DTC lesions and cervical lymph node metastases. The addition of neck PET/MR scan after whole-body PET/CT may provide more favorable diagnostic information. We explored the clinical value of18 F-FDG PET/MR in a head-to-head comparison with PET/CT in loco-regional recurrent and metastatic cervical lymph nodes of differentiated thyroid carcinoma (DTC) patients after comprehensive treatment.18 F-FDG PET/CT and neck PET/MR scans that were performed in DTC patients with suspected recurrence or cervical lymph node metastasis after comprehensive treatment were retrospectively analyzed. Detection rates, diagnostic efficacy, image conspicuity, and measured parameters were compared between18 F-FDG PET/CT and PET/MR. The gold standard was histopathological diagnosis or clinical and imaging follow-up results for more than 6 months. Among the 37 patients enrolled, no suspicious signs of tumor were found in 10 patients, 24 patients had lymph node metastasis, and 3 patients had both recurrence and lymph node metastases. A total of 130 lesions were analyzed, including 3 malignant and 6 benign thyroid nodules, as well as 74 malignant and 47 benign cervical lymph nodes. Compared with PET/CT, PET/MR presented better detection rates (91.5% vs. 80.8%), image conspicuity (2.74 ± 0.60 vs. 1.9 ± 0.50, p < 0.001, especially in complex level II), and sensitivity (80.5% vs. 61.0%). SUVmax differed in benign and malignant lymph nodes in both imaging modalities (p < 0.05). For the same lesion, the SUVmax, SUVmean, and diameters measured by PET/MR and PET/CT were consistent and had significant correlation. In conclusion, compared with18 F-FDG PET/CT, PET/MR was more accurate in determining recurrent and metastatic lesions, both from a patient-based and from a lesion-based perspective. Adding local PET/MR after whole-body PET/CT may be recommended to provide more precise diagnostic information and scope of surgical resection without additional ionizing radiation. Further scaling-up prospective studies and economic benefit analysis are expected. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
37. Multimodality imaging of nitric oxide and nitric oxide synthases
- Author
-
Hong, Hao, Sun, Jiangtao, and Cai, Weibo
- Subjects
- *
NITRIC oxide , *NITRIC-oxide synthases , *NONINVASIVE diagnostic tests , *PATHOLOGICAL physiology , *DRUG development , *ELECTRON paramagnetic resonance , *POSITRON emission tomography , *PHARMACOKINETICS - Abstract
Abstract: Nitric oxide (NO) and NO synthases (NOSs) are crucial factors in many pathophysiological processes such as inflammation, vascular/neurological function, and many types of cancer. Noninvasive imaging of NO or NOS can provide new insights in understanding these diseases and facilitate the development of novel therapeutic strategies. In this review, we will summarize the current state-of-the-art multimodality imaging in detecting NO and NOSs, including optical (fluorescence, chemiluminescence, and bioluminescence), electron paramagnetic resonance (EPR), magnetic resonance (MR), and positron emission tomography (PET). With continued effort over the last several years, these noninvasive imaging techniques can now reveal the biodistribution of NO or NOS in living subjects with high fidelity which will greatly facilitate scientists/clinicians in the development of new drugs and/or patient management. Lastly, we will also discuss future directions/applications of NO/NOS imaging. Successful development of novel NO/NOS imaging agents with optimal in vivo stability and desirable pharmacokinetics for clinical translation will enable the maximum benefit in patient management. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
38. Molecular imaging of β-cells: diabetes and beyond.
- Author
-
Wei, Weijun, Ehlerding, Emily B., Lan, Xiaoli, Luo, Quan-Yong, and Cai, Weibo
- Subjects
- *
TYPE 1 diabetes , *TYPE 2 diabetes , *POSITRON emission tomography , *SINGLE-photon emission computed tomography , *ISLANDS of Langerhans - Abstract
Since diabetes is becoming a global epidemic, there is a great need to develop early β-cell specific diagnostic techniques for this disorder. There are two types of diabetes (i.e. , type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM)). In T1DM, the destruction of pancreatic β-cells leads to reduced insulin production or even absolute insulin deficiency, which consequently results in hyperglycemia. Actually, a central issue in the pathophysiology of all types of diabetes is the relative reduction of β-cell mass (BCM) and/or impairment of the function of individual β-cells. In the past two decades, scientists have been trying to develop imaging techniques for noninvasive measurement of the viability and mass of pancreatic β-cells. Despite intense scientific efforts, only two tracers for positron emission tomography (PET) and one contrast agent for magnetic resonance (MR) imaging are currently under clinical evaluation. β-cell specific imaging probes may also allow us to precisely and specifically visualize transplanted β-cells and to improve transplantation outcomes, as transplantation of pancreatic islets has shown promise in treating T1DM. In addition, some of these probes can be applied to the preoperative detection of hidden insulinomas as well. In the present review, we primarily summarize potential tracers under development for imaging β-cells with a focus on tracers for PET, SPECT, MRI, and optical imaging. We will discuss the advantages and limitations of the various imaging probes and extend an outlook on future developments in the field. Unlabelled Image [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
39. ImmunoPET imaging of tissue factor expression in pancreatic cancer with 89Zr-Df-ALT-836.
- Author
-
Hernandez, Reinier, England, Christopher G., Yang, Yunan, Valdovinos, Hector F., Liu, Bai, Wong, Hing C., Barnhart, Todd E., and Cai, Weibo
- Subjects
- *
PANCREATIC cancer diagnosis , *THROMBOPLASTIN , *POSITRON emission tomography , *PANCREATIC cancer treatment , *GENETIC overexpression , *STATISTICAL correlation - Abstract
Overexpression of tissue factor (TF) has been associated with increased tumor growth, tumor angiogenesis, and metastatic potential in many malignancies, including pancreatic cancer. Additionally, high TF expression was shown to strongly correlate with poor prognoses and decreased survival in pancreatic cancer patients. Herein, we exploited the potential targeting of TF for positron emission tomography (PET) imaging of pancreatic cancer. The TF-targeted tracer was developed through radiolabeling of the anti-human TF monoclonal antibody (ALT-836) with 89 Zr. The tracer was characterized by fluorescence microscopy and flow cytometry assays in BXPC-3 and PANC-1 cells, two pancreatic cancer cell lines with high and low TF expression levels, respectively. Non-invasive PET scans were acquired in tumor-bearing mice injected with 89 Zr-Df-ALT-836. Additionally, ex vivo biodistribution, blocking, and histological studies were performed to establish the affinity and specificity of 89 Zr-Df-ALT-836 for TF in vivo . 89 Zr-labeling of Df-ALT-836 was achieved in high yield and good specific activity. Flow cytometry and microscopy studies revealed no detectable difference in TF-binding affinity between ALT-836 and Df-ALT-836 in vitro . Longitudinal PET scans unveiled a lasting and prominent 89 Zr-Df-ALT-836 uptake in BXPC-3 tumors (peak at 31.5 ± 6.0%ID/g at 48 h post-injection; n = 3), which was significantly abrogated (2.3 ± 0.5%ID/g at 48 h post-injection; n = 3) when mice were pre-injected with a blocking dose (50 mg/kg) of unlabeled ALT-836. Ex vivo biodistribution data confirmed the accuracy of the PET results, and histological analysis correlated high tumor uptake with in situ TF expression. Taken together, these results attest to the excellent affinity and TF-specificity of 89 Zr-Df-ALT-836. With elevated, persistent, and specific accumulation in TF-positive BXPC-3 tumors, PET imaging using 89 Zr-Df-ALT-836 promises to open new avenues for improving future diagnosis, stratification, and treatment response assessment in pancreatic cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
40. Re-assessing the enhanced permeability and retention effect in peripheral arterial disease using radiolabeled long circulating nanoparticles.
- Author
-
England, Christopher G., Im, Hyung-Jun, Feng, Liangzhu, Chen, Feng, Graves, Stephen A., Hernandez, Reinier, Orbay, Hakan, Xu, Cheng, Cho, Steve Y., Nickles, Robert J., Liu, Zhuang, Lee, Dong Soo, and Cai, Weibo
- Subjects
- *
ARTERIAL diseases , *NANOPARTICLES , *NEOVASCULARIZATION , *PERFUSION , *POSITRON emission tomography , *THERAPEUTICS - Abstract
As peripheral arterial disease (PAD) results in muscle ischemia and neovascularization, it has been claimed that nanoparticles can passively accumulate in ischemic tissues through the enhanced permeability and retention (EPR) effect. At this time, a quantitative evaluation of the passive targeting capabilities of nanoparticles has not been reported in PAD. Using a murine model of hindlimb ischemia, we quantitatively assessed the passive targeting capabilities of 64 Cu-labeled PEGylated reduced graphene oxide – iron oxide nanoparticles ( 64 Cu-RGO-IONP-PEG) through the EPR effect using positron emission tomography (PET) imaging. Serial laser Doppler imaging was performed to monitor changes in blood perfusion upon surgical induction of ischemia. Nanoparticle accumulation was assessed at 3, 10, and 17 days post-surgery and found to be highest at 3 days post-surgery, with the ischemic hindlimb displaying an accumulation of 14.7 ± 0.5% injected dose per gram (%ID/g). Accumulation of 64 Cu-RGO-IONP-PEG was lowest at 17 days post-surgery, with the ischemic hindlimb displaying only 5.1 ± 0.5%ID/g. Furthermore, nanoparticle accumulation was confirmed by photoacoustic imaging (PA). The combination of PET and serial Doppler imaging showed that nanoparticle accumulation in the ischemic hindlimb negatively correlated with blood perfusion. Thus, we quantitatively confirmed that 64 Cu-RGO-IONP-PEG passively accumulated in ischemic tissue via the EPR effect, which is reduced as the perfusion normalizes. As 64 Cu-RGO-IONP-PEG displayed substantial accumulation in the ischemic tissue, this nanoparticle platform may function as a future theranostic agent, providing both imaging and therapeutic applications. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
41. VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide in vivo.
- Author
-
Shi, Sixiang, Yang, Kai, Hong, Hao, Chen, Feng, Valdovinos, Hector F., Goel, Shreya, Barnhart, Todd E., Liu, Zhuang, and Cai, Weibo
- Subjects
- *
VASCULAR endothelial growth factors , *TARGETED drug delivery , *GRAPHENE oxide , *TUMOR treatment , *NANOSTRUCTURED materials , *POSITRON emission tomography - Abstract
Although graphene oxide (GO) has recently been considered as a highly attractive nanomaterial for future cancer imaging and therapy, it is still a major challenge to improve its in vivo tumor active targeting efficiency. Here in this full article, we demonstrated the successful and significantly enhanced in vivo tumor vasculature targeting efficacy of well-functionalized GO nanoconjugates by using vascular endothelial growth factor 121 (VEGF121) as the targeting ligand. As-developed GO nanoconjugate exhibits excellent in vivo stability, specific in vitro and in vivo vascular endothelial growth factor receptor (VEGFR) targeting, significantly enhanced tumor accumulation (>8 %ID/g) as well as high tumor-to-muscle contrast, showing great potential for future tumor targeted imaging and therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
42. New radiotracers for imaging of vascular targets in angiogenesis-related diseases.
- Author
-
Hong, Hao, Chen, Feng, Zhang, Yin, and Cai, Weibo
- Subjects
- *
NEOVASCULARIZATION , *POSITRON emission tomography , *RADIOACTIVE tracers , *CARDIOVASCULAR diseases , *INFLAMMATION , *DISEASE progression ,VASCULAR disease diagnosis - Abstract
Tremendous advances over the last several decades in positron emission tomography (PET) and single photon emission computed tomography (SPECT) allow for targeted imaging of molecular and cellular events in the living systems. Angiogenesis, a multistep process regulated by the network of different angiogenic factors, has attracted world-wide interests, due to its pivotal role in the formation and progression of different diseases including cancer, cardiovascular diseases (CVD), and inflammation. In this review article, we will summarize the recent progress in PET or SPECT imaging of a wide variety of vascular targets in three major angiogenesis-related diseases: cancer, cardiovascular diseases, and inflammation. Faster drug development and patient stratification for a specific therapy will become possible with the facilitation of PET or SPECT imaging and it will be critical for the maximum benefit of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
43. Image-guided and tumor-targeted drug delivery with radiolabeled unimolecular micelles.
- Author
-
Guo, Jintang, Hong, Hao, Chen, Guojun, Shi, Sixiang, Zheng, Qifeng, Zhang, Yin, Theuer, Charles P., Barnhart, Todd E., Cai, Weibo, and Gong, Shaoqin
- Subjects
- *
DRUG delivery systems , *MICELLES , *RADIOACTIVE tracers , *BLOCK copolymers , *AMPHIPHILES , *DENDRITIC cells , *ENDOTHELIAL cells - Abstract
Abstract: Unimolecular micelles formed by dendritic amphiphilic block copolymers poly(amidoamine)–poly(l-lactide)-b-poly(ethylene glycol) conjugated with anti-CD105 monoclonal antibody (TRC105) and 1,4,7-triazacyclononane-N, N′, N-triacetic acid (NOTA, a macrocyclic chelator for 64Cu) (abbreviated as PAMAM–PLA-b-PEG–TRC105) were synthesized and characterized. Doxorubicin (DOX), a model anti-cancer drug, was loaded into the hydrophobic core of the unimolecular micelles formed by PAMAM and PLA via physical encapsulation. The unimolecular micelles exhibited a uniform size distribution and pH-sensitive drug release behavior. TRC105-conjugated unimolecular micelles showed a CD105-associated cellular uptake in human umbilical vein endothelial cells (HUVEC) compared with non-targeted unimolecular micelles, which was further validated by cellular uptake in CD105-negative MCF-7 cells. In 4T1 murine breast tumor-bearing mice, 64Cu-labeled targeted micelles exhibited a much higher level of tumor accumulation than 64Cu-labeled non-targeted micelles, measured by serial non-invasive positron emission tomography (PET) imaging and confirmed by biodistribution studies. These unimolecular micelles formed by dendritic amphiphilic block copolymers that synergistically integrate passive and active tumor-targeting abilities with pH-controlled drug release and PET imaging capabilities provide the basis for future cancer theranostics. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
44. Tumor vasculature targeting and imaging in living mice with reduced graphene oxide
- Author
-
Shi, Sixiang, Yang, Kai, Hong, Hao, Valdovinos, Hector F., Nayak, Tapas R., Zhang, Yin, Theuer, Charles P., Barnhart, Todd E., Liu, Zhuang, and Cai, Weibo
- Subjects
- *
TUMOR treatment , *BLOOD vessels , *TARGETED drug delivery , *LABORATORY mice , *GRAPHENE , *NANOSTRUCTURED materials , *POSITRON emission tomography - Abstract
Abstract: Graphene-based nanomaterials have attracted tremendous attention in the field of biomedicine due to their intriguing properties. Herein, we report tumor vasculature targeting and imaging in living mice using reduced graphene oxide (RGO), which was conjugated to the anti-CD105 antibody TRC105. The RGO conjugate, 64Cu–NOTA–RGO–TRC105, exhibited excellent stability in vitro and in vivo. Serial positron emission tomography (PET) imaging studies non-invasively assessed the pharmacokinetics and demonstrated specific targeting of 64Cu–NOTA–RGO–TRC105 to 4T1 murine breast tumors in vivo, compared to non-targeted RGO conjugate (64Cu–NOTA–RGO). In vivo (e.g., blocking 4T1 tumor uptake with excess TRC105), in vitro (e.g., flow cytometry), and ex vivo (e.g., histology) experiments confirmed the specificity of 64Cu–NOTA–RGO–TRC105 for tumor vascular CD105. Since RGO exhibits desirable properties for photothermal therapy, the tumor-specific RGO conjugate developed in this work may serve as a promising theranostic agent that integrates imaging and therapeutic components. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
45. In vivo targeting and positron emission tomography imaging of tumor vasculature with 66Ga-labeled nano-graphene
- Author
-
Hong, Hao, Zhang, Yin, Engle, Jonathan W., Nayak, Tapas R., Theuer, Charles P., Nickles, Robert J., Barnhart, Todd E., and Cai, Weibo
- Subjects
- *
IMAGING of cancer , *POSITRON emission tomography , *GRAPHENE , *NANOSTRUCTURED materials , *GALLIUM , *TARGETED drug delivery , *ANIMAL models of cancer , *PHARMACOKINETICS - Abstract
Abstract: The goal of this study was to employ nano-graphene for tumor targeting in an animal tumor model, and quantitatively evaluate the pharmacokinetics and tumor targeting efficacy through positron emission tomography (PET) imaging using 66Ga as the radiolabel. Nano-graphene oxide (GO) sheets with covalently linked, amino group-terminated six-arm branched polyethylene glycol (PEG; 10 kDa) chains were conjugated to NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid, for 66Ga-labeling) and TRC105 (an antibody that binds to CD105). Flow cytometry analyses, size measurements, and serum stability studies were performed to characterize the GO conjugates before in vivo investigations in 4T1 murine breast tumor-bearing mice, which were further validated by histology. TRC105-conjugated GO was specific for CD105 in cell culture. 66Ga-NOTA-GO-TRC105 and 66Ga-NOTA-GO exhibited excellent stability in complete mouse serum. In 4T1 tumor-bearing mice, these GO conjugates were primarily cleared through the hepatobiliary pathway. 66Ga-NOTA-GO-TRC105 accumulated quickly in the 4T1 tumors and tumor uptake remained stable over time (3.8 ± 0.4, 4.5 ± 0.4, 5.8 ± 0.3, and 4.5 ± 0.4 %ID/g at 0.5, 3, 7, and 24 h post-injection respectively; n = 4). Blocking studies with unconjugated TRC105 confirmed CD105 specificity of 66Ga-NOTA-GO-TRC105, which was corroborated by biodistribution and histology studies. Furthermore, histological examination revealed that targeting of NOTA-GO-TRC105 is tumor vasculature CD105 specific with little extravasation. Successful demonstration of in vivo tumor targeting with GO, along with the versatile chemistry of graphene-based nanomaterials, makes them suitable nanoplatforms for future biomedical research such as cancer theranostics. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
46. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging
- Author
-
Xiao, Yuling, Hong, Hao, Javadi, Alireza, Engle, Jonathan W., Xu, Wenjin, Yang, Yunan, Zhang, Yin, Barnhart, Todd E., Cai, Weibo, and Gong, Shaoqin
- Subjects
- *
MICELLES , *DRUG delivery systems , *POSITRON emission tomography , *COPOLYMERS , *LABORATORY mice , *PEPTIDES , *INTEGRINS - Abstract
Abstract: A multifunctional unimolecular micelle made of a hyperbranched amphiphilic block copolymer was designed, synthesized, and characterized for cancer-targeted drug delivery and non-invasive positron emission tomography (PET) imaging in tumor-bearing mice. The hyperbranched amphiphilic block copolymer, Boltorn® H40-poly(L-glutamate-hydrazone-doxorubicin)-b-poly(ethylene glycol) (i.e., H40-P(LG-Hyd-DOX)-b-PEG), was conjugated with cyclo(Arg-Gly-Asp-D-Phe-Cys) peptides (cRGD, for integrin αvβ3 targeting) and macrocyclic chelators (1,4,7-triazacyclononane-N, N’, N’’-triacetic acid [NOTA], for 64Cu-labeling and PET imaging) (i.e., H40-P(LG-Hyd-DOX)-b-PEG-OCH3/cRGD/NOTA, also referred to as H40-DOX-cRGD). The anti-cancer drug, doxorubicin (DOX) was covalently conjugated onto the hydrophobic segments of the amphiphilic block copolymer arms (i.e., PLG) via a pH-labile hydrazone linkage to enable pH-controlled drug release. The unimolecular micelles exhibited a uniform size distribution and pH-sensitive drug release behavior. cRGD-conjugated unimolecular micelles (i.e., H40-DOX-cRGD) exhibited a much higher cellular uptake in U87MG human glioblastoma cells due to integrin αvβ3-mediated endocytosis than non-targeted unimolecular micelles (i.e., H40-DOX), thereby leading to a significantly higher cytotoxicity. In U87MG tumor-bearing mice, H40-DOX-cRGD-64Cu also exhibited a much higher level of tumor accumulation than H40-DOX-64Cu, measured by non-invasive PET imaging and confirmed by biodistribution studies and ex vivo fluorescence imaging. We believe that unimolecular micelles formed by hyperbranched amphiphilic block copolymers that synergistically integrate passive and active tumor-targeting abilities with pH-controlled drug release and PET imaging capabilities provide the basis for future cancer theranostics. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
47. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging
- Author
-
Yang, Xiaoqiang, Hong, Hao, Grailer, Jamison J., Rowland, Ian J., Javadi, Alireza, Hurley, Samuel A., Xiao, Yuling, Yang, Yunan, Zhang, Yin, Nickles, Robert J., Cai, Weibo, Steeber, Douglas A., and Gong, Shaoqin
- Subjects
- *
NANOMEDICINE , *NANOPARTICLES , *DRUG delivery systems , *PARAMAGNETISM , *MAGNETIC properties of iron oxides , *POSITRON emission tomography , *MAGNETIC resonance imaging of cancer , *ANTINEOPLASTIC agents , *TARGETED drug delivery - Abstract
Abstract: Multifunctional and water-soluble superparamagnetic iron oxide (SPIO) nanocarriers were developed for targeted drug delivery and positron emission tomography/magnetic resonance imaging (PET/MRI) dual-modality imaging of tumors with integrin αvβ3 expression. An anticancer drug was conjugated onto the PEGylated SPIO nanocarriers via pH-sensitive bonds. Tumor-targeting ligands, cyclo(Arg-Gly-Asp-d-Phe-Cys) (c(RGDfC)) peptides, and PET 64Cu chelators, macrocyclic 1,4,7-triazacyclononane-N, N′, N″-triacetic acid (NOTA), were conjugated onto the distal ends of the PEG arms. The effectiveness of the SPIO nanocarriers as an MRI contrast agent was evaluated via an in vitro r2 MRI relaxivity measurement. cRGD-conjugated SPIO nanocarriers exhibited a higher level of cellular uptake than cRGD-free ones in vitro. Moreover, cRGD-conjugated SPIO nanocarriers showed a much higher level of tumor accumulation than cRGD-free ones according to non-invasive and quantitative PET imaging, and ex vivo biodistribution studies. Thus, these SPIO nanocarriers demonstrated promising properties for combined targeted anticancer drug delivery and PET/MRI dual-modality imaging of tumors. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.